These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18850558)

  • 1. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma.
    Hommer A; Thygesen J; Ferreras A; Wickstrom J; Friis MM; Buchholz P; Walt JG
    Eur J Ophthalmol; 2008; 18(5):778-86. PubMed ID: 18850558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
    Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F
    J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
    Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.
    Oztürk F; Ermiş SS; Inan UU; Aşagidag A; Yaman S
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
    Nguyen QH; Earl M
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
    Hommer A; Kapik B; Shams N;
    Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
    Inatani M; Orii Y; Iwasaki K; Arimura S; Sunagawa H; Shiokawa M; Inoue K; Sakono T; Sakono T; Kuwamura R; Yoshida A; Oi J; Kuwayama Y; Kano K; Kido N; Matsuyama A; Ozaki M; Abe H; Inoue C; Nakagawa S; Musashi K; Kanamori A; Lee J; Otani S; Aoki R; Tanabe H; Nakakura S; Suzuki K; Sagara T; Saito Y; Sameshima M; Urahashi M; Watanabe-Kitamura F; Inoue T; Kagaya F; Murai Y; Mori S; Ueda K; Kurimoto T; Yamada-Nakanishi Y; Nakamura M; Yamashita T; Ishiyama S; Manabe S; Takaki K; Hayashi K; Ishida A; Tsutsui A; Manabe K; Tanito M
    Adv Ther; 2023 Sep; 40(9):4074-4092. PubMed ID: 37452961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers].
    Carrasco Font C; Arias Puente A; García Sáenz MC; Villarejo Díaz-Maroto I
    Arch Soc Esp Oftalmol; 2004 Apr; 79(4):163-8. PubMed ID: 15124072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
    Frampton JE
    Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%.
    Chan K; Testa M; McCluskey P
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):372-6. PubMed ID: 17803436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis.
    Lachaine J; Hodge WG; Steffensen I; Murray C; Barnes D; Foerster V; Ducruet T; Mensinkai S
    Can J Ophthalmol; 2008 Feb; 43(1):33-41. PubMed ID: 18219345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
    Baiza-Durán LM; Alvarez-Delgado J; Contreras-Rubio AY; Medrano-Palafox J; De Luca-Brown A; Casab-Rueda H; Cortés-Gastélum MA; Garcidueñas-Mejía MJ; Gómez-Bastar P; Gil-Carrasco F; Hartleben-Matkin C; Jiménez-Román J; Moreno-Marín ML; Paczka-Zapata JA; Velasco-Gallegos G; Vergara-Sinta M
    Ann Ophthalmol (Skokie); 2009; 41(3-4):174-8. PubMed ID: 20214051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE; Lai J
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma.
    van Gestel A; Webers CA; Severens JL; Beckers HJ; Jansonius NM; Hendrikse F; Schouten JS
    Acta Ophthalmol; 2012 Feb; 90(1):20-31. PubMed ID: 22289192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.